NCT06751108View on ClinicalTrials.gov

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

Active, not recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
NSCLC, Non Small Cell Lung Cancer
Interventions
DRUG

Corticosteroids (CS)

Concomitant use of immune checkpoint inhibitors and corticosteroids

DRUG

Immune Checkpoint Inhibitors

Non-concomitant use of corticosteroids

Trial Locations (1)

Unknown

Seoul National University, Seoul

All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Catholic Medical Center of Korea

UNKNOWN

lead

Seoul National University

OTHER

NCT06751108 - Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients | Biotech Hunter | Biotech Hunter